Smoking Cessation and Cardiovascular Disease Risk Factors: Results from the Third National Health and Nutrition Examination Survey

Background Cigarette smoking is a major risk factor for the development and progression of cardiovascular disease. While smoking is associated with increased levels of inflammatory markers and accelerated atherosclerosis, few studies have examined the impact of smoking cessation on levels of inflammatory markers. The degree and rate at which inflammation subsides after smoking cessation are uncertain. It also remains unclear as to whether traditional risk factors can adequately explain the observed decline in cardiovascular risk following smoking cessation. Methods and Findings Using data from 15,489 individuals who participated in the Third National Health and Nutrition Examination Survey (NHANES III), we analyzed the association between smoking and smoking cessation on levels of inflammatory markers and traditional cardiovascular risk factors. In particular, we examined changes in C-reactive protein, white blood cell count, albumin, and fibrinogen. Inflammatory markers demonstrated a dose-dependent and temporal relationship to smoking and smoking cessation. Both inflammatory and traditional risk factors improved with decreased intensity of smoking. With increased time since smoking cessation, inflammatory markers resolved more slowly than traditional cardiovascular risk factors. Conclusion Inflammatory markers may be more accurate indicators of atherosclerotic disease. Inflammatory markers returned to baseline levels 5 y after smoking cessation, consistent with the time frame associated with cardiovascular risk reduction observed in both the MONICA and Northwick Park Heart studies. Our results suggest that the inflammatory component of cardiovascular disease resulting from smoking is reversible with reduced tobacco exposure and smoking cessation.

[1]  E. Fleck,et al.  C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells , 2004, Circulation.

[2]  L. Appel,et al.  Relationship between systemic markers of inflammation and serum beta-carotene levels. , 2001, Archives of internal medicine.

[3]  N J Wald,et al.  Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence , 1997, BMJ.

[4]  J. L. Harrison,et al.  The Government Printing Office , 1968, American Journal of Pharmaceutical Education.

[5]  S. Verma,et al.  Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II , 2003, Circulation.

[6]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[7]  Ratnam,et al.  The regulation of superoxide generation and nitric oxide synthesis by C‐reactive protein , 1998, Immunology.

[8]  D. Cook,et al.  GIVING UP SMOKING AND THE RISK OF HEART ATTACKS A report from The British Regional Heart Study , 1986, The Lancet.

[9]  P. Vallance,et al.  Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? , 1997, The Lancet.

[10]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[11]  P. Ridker,et al.  C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  J. Volanakis,et al.  Molecular genetics, structure, and function of C-reactive protein , 1991, Immunologic research.

[13]  Jiang He,et al.  Relationship between Cigarette Smoking and Novel Risk Factors for Cardiovascular Disease in the United States , 2003, Annals of Internal Medicine.

[14]  A. C. Robertson,et al.  DESIGN AND USE OF PLASTIC TENTS FOR ISOLATION OF PATIENTS PRONE TO INFECTION , 1968 .

[15]  N. Rigotti,et al.  Cigarette smoking and coronary heart disease: risks and management. , 1996, Cardiology clinics.

[16]  M. Kutryk,et al.  C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link Between C-Reactive Protein and Cardiovascular Disease , 2004, Circulation.

[17]  Å. Westin,et al.  Effect of smoking reduction and cessation on cardiovascular risk factors. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[18]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[19]  D. Panagiotakos,et al.  Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. , 2004, The American journal of medicine.

[20]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[21]  P. Mendola,et al.  Blood lead levels and sexual maturation in U.S. girls: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Environmental health perspectives.

[22]  T. Meade,et al.  Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study , 1993, The Lancet.

[23]  N. Rifai.  C-reactive protein and coronary heart disease , 2007, Cardiovascular Toxicology.

[24]  J. Deckers,et al.  Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey. , 1999, European heart journal.

[25]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[26]  G. Lozanski,et al.  Do Post‐transcriptional Mechanisms Participate in Induction of C‐reactive Protein and Serum Amyloid A by IL‐6 and IL‐I? a , 1995, Annals of the New York Academy of Sciences.

[27]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[28]  N. Benowitz.  Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. , 2003, Progress in cardiovascular diseases.

[29]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[30]  Meinders Ae,et al.  [Atherosclerosis and inflammation: the role of C-reactive protein]. , 2003 .

[31]  S. Johansson,et al.  Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. , 1983, British heart journal.

[32]  V. Poli,et al.  Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo. , 1997, The Biochemical journal.

[33]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[34]  James T. Willerson,et al.  Modulation of C-Reactive Protein-Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001, Circulation.

[35]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[36]  T. Strandberg,et al.  C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[37]  A. Agrawal,et al.  Overexpressed nuclear factor‐κB can participate in endogenous C‐reactive protein induction, and enhances the effects of C/EBPβ and signal transducer and activator of transcription‐3 , 2003, Immunology.

[38]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[39]  T. Meade,et al.  EFFECTS OF CHANGES IN SMOKING AND OTHER CHARACTERISTICS ON CLOTTING FACTORS AND THE RISK OF ISCHAEMIC HEART DISEASE , 1987, The Lancet.

[40]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[41]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[42]  A. Dobson,et al.  How soon after quitting smoking does risk of heart attack decline? , 1991, Journal of clinical epidemiology.

[43]  S. Glantz,et al.  Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. , 1997, Circulation.

[44]  M. Szklo,et al.  Active and passive smoking are associated with increased carotid wall thickness. The Atherosclerosis Risk in Communities Study. , 1994, Archives of internal medicine.

[45]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[46]  Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.

[47]  E. Falk,et al.  Pathology of the Coronary Arteries in Smokers and Non-Smokers , 1999, Journal of cardiovascular risk.

[48]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[49]  R. Kronmal,et al.  The temporal pattern of reduction of mortality risk after smoking cessation. , 1990, American Journal of Preventive Medicine.

[50]  Global tobacco treaty enters into force with 57 countries already committed. , 2005, Indian journal of medical sciences.

[51]  J. Danesh,et al.  Risk factors for coronary heart disease and acute-phase proteins. A population-based study. , 1999, European heart journal.

[52]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[53]  R. Frye,et al.  T-Cell–Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes , 2002, Circulation.

[54]  W. Sluiter,et al.  Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. , 1996, Atherosclerosis.

[55]  J. Borensztajn,et al.  Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. , 2002, The Biochemical journal.

[56]  S. Chakraborti,et al.  Complement activation in heart diseases. Role of oxidants. , 2000, Cellular signalling.

[57]  J. Mackeith.  DISCHARGE OF VIOLENT PATIENTS , 1975, The Lancet.

[58]  A. Meinders,et al.  [Atherosclerosis and inflammation: the role of C-reactive protein]. , 2003, Nederlands tijdschrift voor geneeskunde.

[59]  N. Cook,et al.  C-reactive protein and coronary heart disease. , 2004, The New England journal of medicine.

[60]  Neil R. Powe,et al.  The Atherosclerosis Risk in Communities Study , 2006 .

[61]  T. Pechacek,et al.  How acute and reversible are the cardiovascular risks of secondhand smoke? , 2004, BMJ : British Medical Journal.

[62]  T. Pearson.  New Tools for Coronary Risk Assessment: What Are Their Advantages and Limitations? , 2002, Circulation.

[63]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[64]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[65]  S. Shapiro,et al.  Decline in the risk of myocardial infarction among women who stop smoking. , 1990, The New England journal of medicine.

[66]  D. Mannino,et al.  Serum carotenoid concentrations in US children and adolescents. , 2002, The American journal of clinical nutrition.

[67]  A. Agrawal,et al.  The Rel Family Member P50 Mediates Cytokine-Induced C-Reactive Protein Expression by a Novel Mechanism1 , 2000, The Journal of Immunology.